ReposiTrak (TRAK)
NYSE:TRAK
Want to see TRAK full AI Analyst Report?
Top Page
ReposiTrak
(NYSE:TRAK)
Select Model
Select Model
Rating:75Outperform
Price Target:
$11.00
▲(35.14% Upside)
Action:Reiterated
Date:05/18/26
The score is driven primarily by strong financial quality (high margins, low leverage, solid cash conversion) and a generally positive earnings-call narrative around recurring revenue and disciplined spending/capital returns. These are tempered by data-quality concerns in the most recent TTM financial snapshot, near-term revenue timing headwinds and execution risks in traceability initiatives, and a technical picture that is improving short-term but still below the 200-day trend.
Positive Factors
High recurring revenue mix
Converting most sales to recurring SaaS improves revenue predictability, reduces churn-driven volatility, and scales monetization across supplier networks. This structural shift underpins steadier cash flow, easier forecasting, and supports reinvestment and capital returns over the medium term.
Negative Factors
Supplier data quality issues
Persistent high error rates force significant remediation costs and development of AI-based correction. Structurally, poor upstream data raises implementation friction, slows network onboarding, increases professional services needs, and could limit the pace at which large retailer mandates translate into scalable revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
High recurring revenue mix
Converting most sales to recurring SaaS improves revenue predictability, reduces churn-driven volatility, and scales monetization across supplier networks. This structural shift underpins steadier cash flow, easier forecasting, and supports reinvestment and capital returns over the medium term.
Read all positive factors
ReposiTrak Key Performance Indicators (KPIs)
ReposiTrak (TRAK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$183.73M
Dividend Yield0.57%
Average Volume (3M)74.89K
Price to Earnings (P/E)17.4
Beta (1Y)1.38
Revenue Growth6.55%
EPS Growth11.41%
CountryUS
Employees73
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.39
Shares Outstanding18,173,565
10 Day Avg. Volume93,616
30 Day Avg. Volume74,886
Financial Highlights & Ratios
PEG Ratio2.57
Price to Book (P/B)7.25
Price to Sales (P/S)15.87
P/FCF Ratio42.70
Enterprise Value/Market Cap-140.84
Enterprise Value/Revenue-1.10K
Enterprise Value/Gross Profit-1.30K
Enterprise Value/Ebitda-3.02K
Forecast
1Y Price Target
$16.00Price Target Upside96.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$23.63M
ReposiTrak Business Overview & Revenue Model
Company Description
ReposiTrak, Inc., a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance a...
How the Company Makes Money
ReposiTrak makes money primarily by charging customers recurring fees for access to its cloud-based compliance and supply-chain management platform. Key revenue streams typically include: (1) subscription/SaaS fees for platform access and ongoing ...
ReposiTrak Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Oct 05, 2026
Earnings Call Sentiment Positive
The call emphasized strong margin expansion, balance sheet strength (zero bank debt, ~$26.4M cash), high-quality recurring revenue (now >98%), active capital return programs, patent filings, and early commercial wins for touchless traceability. Key challenges include a flat Q3 revenue due to timing shifts from FDA deadline extensions, a significant increase in tax expense as NOL benefits expire, substantial supplier data quality issues that require AI remediation, and longer sales cycles for traceability with some uncertainty around the Spar Group partnership's near-term revenue impact. Overall, the positives—notably profitability, cash generation, recurring revenue conversion, IP, and shareholder returns—outweigh the near-term timing and execution risks.Positive Updates
High Proportion of Recurring Revenue
Recurring revenue increased from ~62% of total revenue in fiscal 2020 to more than 98% today; converted more than $7.0M of former one-time revenue into recurring SaaS streams since fiscal 2020, improving predictability and revenue quality.
Negative Updates
Flat Q3 Revenue and Timing Headwinds
Third quarter fiscal 2026 revenue was $5.9M, essentially flat YoY (0% change). Prior-year quarter (Mar 2025) benefited from accelerated traceability onboarding (~16% growth) tied to original FDA deadlines; the FSMA 204 compliance deadline extension created a timing shift that reduced onboarding activity in the current quarter.
Read all updates
Q3-2026 Updates
Positive
Negative
High Proportion of Recurring Revenue
Recurring revenue increased from ~62% of total revenue in fiscal 2020 to more than 98% today; converted more than $7.0M of former one-time revenue into recurring SaaS streams since fiscal 2020, improving predictability and revenue quality.
Read all positive updates
Company Guidance
Management guided to an ongoing effective tax rate of roughly 20% (Q3 was ~18% after a ~200% YoY tax-expense increase of ≈$300k), and said modernization/AI initiatives should not drive any meaningful increase in cash operating expenses or capital expenditures; they also expect the Spar Group collaboration to show financial impact in roughly 6–9 months and traceability revenue to accelerate later in the year. Key metrics cited: Q3 revenue $5.9M (flat YoY), YTD revenue $17.7M (+5% YoY), operating cash flow for the first nine months $6.0M, cash of ~ $26.4M and zero bank debt (net cash grew from ~$13.7M in FY2020 to nearly $28M by FY25, ~16% CAGR). The company emphasized recurring revenue now >98% (up from ~62% in FY2020 after converting >$7M of one‑time revenue and eliminating ≈$2M of low‑margin revenue), reduced operating expenses since FY2020 (from ≈$19M to ≈$16M), Q3 operating expenses down 12% to $3.6M (YTD down 4% to $11.7M), Q3 income from operations up 24% to ≈$2.3M (YTD +28% to $6.0M), Q3 GAAP net income ≈$2.0M (basic EPS $0.11; diluted $0.10), YTD GAAP net income $5.5M (YTD diluted EPS $0.28), net margins expanded from ~8% several years ago to north of 30%, share repurchases of 144k shares for ~$1.8M in FY26 YTD (2.3M total repurchased for ~$15M at an average ~$6.60/share; avg price on recent buybacks ~$12.50; $6M remaining authorization), 175k preferred shares redeemed (≈161k preferred shares remain outstanding), a $0.02 quarterly dividend declared (third consecutive annual 10% increase since 2022), and two new patent filings (now nine U.S. patents).ReposiTrak Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
88
Very Positive
Cash Flow
76
Positive
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.47M | 22.61M | 20.45M | 19.10M | 18.05M | 21.01M |
| Gross Profit | 19.96M | 18.92M | 17.04M | 15.79M | 14.86M | 13.10M |
| EBITDA | 8.58M | 8.95M | 7.61M | 7.11M | 5.38M | 5.41M |
| Net Income | 7.29M | 6.98M | 5.96M | 5.59M | 4.00M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 57.38B | 55.33M | 51.60M | 50.58M | 49.32M | 55.05M |
| Cash, Cash Equivalents and Short-Term Investments | 26.41B | 28.57M | 25.15M | 23.99M | 21.46M | 24.07M |
| Total Debt | 349.46M | 509.97K | 545.10K | 747.11K | 2.97M | 6.70M |
| Total Liabilities | 6.88B | 5.81M | 4.74M | 4.70M | 6.42M | 9.91M |
| Stockholders Equity | 50.49B | 49.52M | 46.85M | 45.88M | 42.90M | 45.14M |
Cash Flow | ||||||
| Free Cash Flow | 7.50M | 8.40M | 6.89M | 7.96M | 6.05M | 5.08M |
| Operating Cash Flow | 7.52M | 8.42M | 6.96M | 8.86M | 6.10M | 5.40M |
| Investing Cash Flow | -3.04M | 169.00 | -100.71K | -903.19K | 1.32M | -318.87K |
| Financing Cash Flow | -6.18M | -5.01M | -5.70M | -5.43M | -10.03M | -1.36M |
ReposiTrak Technical Analysis
Positive
8.14
Price Trends
8.49
Positive
9.34
Positive
12.23
Negative
Market Momentum
0.38
Positive
61.42
Neutral
76.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAK, the sentiment is Positive. The current price of 8.14 is below the 20-day moving average (MA) of 9.65, below the 50-day MA of 8.49, and below the 200-day MA of 12.23, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 61.42 is Neutral, neither overbought nor oversold. The STOCH value of 76.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRAK.
ReposiTrak Risk Analysis
ReposiTrak disclosed 26 risk factors in its most recent earnings report. ReposiTrak reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ReposiTrak Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $183.73M | 17.42 | 0.06% | 0.57% | 6.55% | 11.41% | |
62 Neutral | $306.50M | 138.67 | 1.20% | ― | 2.89% | ― | |
62 Neutral | $290.56M | -20.35 | -30.68% | 14.78% | -16.07% | -85.04% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
48 Neutral | $246.83M | -16.16 | -10.61% | ― | -9.70% | 61.30% |
* Technology Sector Average
TRAK
ReposiTrak
10.11
-11.74
-53.73%
EGHT
8X8
2.20
0.61
38.36%
MKTW
MarketWise
17.99
2.20
13.95%
SMRT
SmartRent
1.28
0.44
52.38%
ReposiTrak Corporate Events
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
ReposiTrak Reports Stable Revenue and Higher Profitability
Positive
May 18, 2026
ReposiTrak, an AI-driven supply chain and food safety platform, reported third-quarter fiscal 2026 results on May 14, 2026, showing flat quarterly revenue at $5.9 million year over year but a 24% rise in operating income to $2.3 million as operati...
Dividends
ReposiTrak Initiates Regular Quarterly Cash Dividend Program
Positive
Mar 24, 2026
On March 20, 2026, ReposiTrak, Inc. announced it had declared a quarterly cash dividend of $0.02 per share, equivalent to $0.08 per share on an annualized basis, on its common stock. The dividend is payable on or about May 15, 2026 to stockholders...
Business Operations and StrategyPrivate Placements and Financing
ReposiTrak Subsidiary Extends $4 Million Note to SPAR
Positive
Mar 20, 2026
On March 16, 2026, PC Group, Inc., a subsidiary of ReposiTrak, Inc., extended a senior unsecured promissory note of up to $4 million to SPAR Marketing Force, Inc., structured as a $3 million initial advance and an additional $1 million tranche ava...
Business Operations and StrategyExecutive/Board Changes
ReposiTrak Strengthens Board With Return of Industry Veteran
Positive
Mar 17, 2026
On March 17, 2026, ReposiTrak announced that James R. Gillis, CEO of MA advisory firm Gillis Associates Inc., rejoined its board of directors effective March 13, 2026, bringing more than 35 years of experience in retail supply chain management, M...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
ReposiTrak posts strong Q2 growth and dividend hike
Positive
Feb 19, 2026
For the second fiscal quarter ended December 31, 2025, ReposiTrak reported a 7% revenue increase to $5.9 million and a 34% jump in operating income to $1.8 million, lifting operating margin to 31%. GAAP net income rose to $1.7 million, with net in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.